We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

1 hedge funds and large institutions have $21.1K invested in Cymabay Therapeutics in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 198 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 200 → 1 (-199)

100% less funds holding in top 10

Funds holding in top 10: 10 → 0 (-10)

100% less capital invested

Capital invested by funds: $2.73B → $21.1K (-$2.73B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 198

Holders
1
Holders Change
-199
Holders Change %
-99.5%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-10
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
198
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$262M
2
BlackRock
BlackRock
New York
-$227M
3
RCM
RA Capital Management
Massachusetts
-$164M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$149M
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$144M
Name Holding Trade Value Shares
Change 		Change in
Stake
TC
151
TwinBeech Capital
New York
– -$265K -11,230 Closed
PL
152
Parkwood LLC
Ohio
– -$264K -11,191 Closed
XT
153
XTX Topco
Cayman Islands
– -$254K -10,767 Closed
Cambridge Investment Research Advisors
154
Cambridge Investment Research Advisors
Iowa
– -$249K -10,533 Closed
TRCT
155
Tower Research Capital (TRC)
New York
– -$248K -10,517 Closed
CA
156
Cetera Advisors
Colorado
– -$246K -10,431 Closed
Verition Fund Management
157
Verition Fund Management
Connecticut
– -$240K -10,170 Closed
PI
158
PEAK6 Investments
Illinois
– -$236K -10,006 Closed
AA
159
AlphaCentric Advisors
Puerto Rico
– -$236K -10,000 Closed
SO
160
STRS Ohio
Ohio
– -$222K -9,400 Closed
AI
161
Atom Investors
Texas
– -$214K -9,070 Closed
CGL
162
Clarius Group LLC
Washington
– -$211K -8,938 Closed
Canada Life
163
Canada Life
Manitoba, Canada
– -$198K -8,424 Closed
SSG
164
Summit Securities Group
New York
– -$199K -8,405 Closed
BC
165
BIT Capital
Germany
– -$194K -8,206 Closed
PNC Financial Services Group
166
PNC Financial Services Group
Pennsylvania
– -$193K -8,179 Closed
MLICM
167
Metropolitan Life Insurance Company (MetLife)
New York
– -$152K -6,447 Closed
EC
168
EntryPoint Capital
New York
– -$150K -6,338 Closed
SG Americas Securities
169
SG Americas Securities
New York
– -$113K -4,780 Closed
VEA
170
Virtus ETF Advisers
New York
– -$101K -4,278 Closed
QL
171
Quarry LP
New York
– -$94.5K -4,000 Closed
TAM
172
Tucker Asset Management
Colorado
– -$88.6K -3,749 Closed
WIA
173
Wetzel Investment Advisors
Indiana
– -$71K -3,000 Closed
A
174
AJOVista
Massachusetts
– -$42.4K -1,794 Closed
TC
175
Truvestments Capital
Florida
– -$32.2K -1,364 Closed
4 5 6
7
8

CBAY Hedge Fund Activity: Q1 2024 in Review

1 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q1 2024, worth a combined $21.1K — down 100% from $2.73B a quarter earlier.

Sellers outnumbered buyers: 198 funds closed out of CBAY and 0 opened new positions — a net loss of 198 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $262M sold.

  • 1 institutional investor held Cymabay Therapeutics (CBAY) as of Q1 2024, down from 200 in Q4 2023.
  • Funds reported $21.1K of Cymabay Therapeutics stock for Q1 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Cymabay Therapeutics positions in Q1 2024 and 198 closed out, a net change of -198 holders.
  • The largest Cymabay Therapeutics seller in Q1 2024 was Avoro Capital Advisors, an estimated $262M sold.

Based on aggregated 13F filings for Q1 2024.